Home » Newsletters » BioWorld Science

BioWorld Science

May 4, 2022

View Archived Issues

GTX-0196 shows complete tumor growth suppression in models of AML

Storm Therapeutics divulges new METTL3 inhibitors

New MRGPRX2 antagonists identified at GlaxoSmithKline

PRISM BioLab discovers Notch signaling inhibitors

Leukos Biotech patents serotonin 5-HT1B receptor antagonists

Ingenew BioPharma synthesizes new IL-1beta, IL-6 and TNF-alpha release inhibitors

In times of need, fat cells take on immune functions

Janssen describes discovery of improved Mcl-1 inhibitor JNJ-4355

MJFF grant supports Asceneuron's preclinical evaluation of ASN-51 for Parkinson's disease

Dianthus closes series A financing to support development of antibody complement therapeutics

CRD-1600 demonstrates robust immune modulatory properties in vitro and in vivo

Studies show KRAS G12C inhibitor APG-1842 is potent, bioavailable and highly selective

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...